share_log

Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency

Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency

火箭製藥公司宣佈RP-L301治療丙酮酸激酶缺乏症第一階段試驗的最新陽性初步臨牀數據
Benzinga Real-time News ·  2021/03/22 19:03

— Updated Data Demonstrate Sustained Improvements in Hemoglobin to Normal Range at 6-months in First Patient and Similar 3-month Improvements in Second Patient Treated —

-最新數據顯示，第一名患者的血紅蛋白在6個月後持續改善至正常範圍，第二名接受治療的患者的血紅蛋白在3個月內也有類似的改善-

— Maintained Safety and Tolerability of RP-L301 up to 6-months Post-treatment —

-維護 RP-L301在治療後6個月內的安全性和耐受性

— Long-Term Data on Track for 2H2021 —

-2021年下半年的長期數據已步入正軌-

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論